Claims for Patent: 10,071,992

Summary for Patent: 10,071,992

Title:	Diacylglycerol acyl transferase 2 inhibitors
Abstract:	Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Inventor(s):	Boehm; Markus (Mansfield, MA), Cabral; Shawn (Groton, CT), Dowling; Matthew S. (Old Lyme, CT), Futatsugi; Kentaro (Quincy, MA), Huard; Kim (Medford, MA), Lee; Esther Cheng Yin (Brookline, MA), Londregan; Allyn T. (Barrington, RI), Polivkova; Jana (Mystic, CT), Price; David A. (Concord, MA), Li; Qifang (Stonington, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	15/674,914
Patent Claims:	1. A compound of Formula (I) ##STR00030## wherein D.sup.1 and D.sup.2 are each independently N or CH; R.sup.1 is H, or (C.sub.1-C.sub.2)alkyl optionally substituted with one or two substituents each independently selected from fluoro and (C.sub.3-C.sub.6)cycloalkyl; R.sup.2 is H or fluoro; R.sup.3 is, ##STR00031## R.sup.4 is H, cyano, or (C.sub.1-C.sub.4)alkyl optionally substituted with one or two substituents each independently selected from OH and --S(O).sub.2R.sup.6; R.sup.5 is H or --OH; and R.sup.6 is (C.sub.1-C.sub.4)alkyl; or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 having the Formula (Ia) ##STR00032## or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R.sup.3 is ##STR00033## 4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R.sup.3 is ##STR00034## 5. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is methyl. 6. The compound of claim 4 or a pharmaceutically acceptable salt thereof wherein R.sup.1 is methyl. 7. The compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is H, --CH.sub.2OH, or cyano. 8. The compound: (S)-2-(5-((3-Ethoxy-5-fluoropyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrof- uran-3-yl)pyrimidine-5-carboxamide; N-(2-cyanopropan-2-yl)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)pyrim- idine-5-carboxamide; 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(3-methyl-1,1-dioxidotetr- ahydrothiophen-3-yl)pyrimidine-5-carboxamide; 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(1-hydroxy-2-methylpropan- -2-yl)pyrimidine-5-carboxamide; (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl- )pyrimidine-5-carboxamide; (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(3-(hydroxymethyl)tet- rahydrofuran-3-yl)pyrimidine-5-carboxamide; (R)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(3-(hydroxymethyl)tet- rahydrofuran-3-yl)pyrimidine-5-carboxamide; 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(2-methyl-1-(methylsulfon- yl)propan-2-yl)pyrimidine-5-carboxamide; (S)-2-(5-((3-(2-fluoroethoxy)pyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydro- furan-3-yl)pyrimidine-5-carboxamide; 3-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(1-hydroxy-2-methylpropan- -2-yl)-1,2,4-triazine-6-carboxamide; N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyr- idin-3-yl)pyrimidine-5-carboxamide; (S)-3-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl- )-1,2,4-triazine-6-carboxamide; N-(1,1-dioxidotetrahydrothiophen-3-yl)-2-(5-((3-ethoxypyridin-2-yl)oxy)py- ridin-3-yl)pyrimidine-5-carboxamide; (R)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl- )pyrimidine-5-carboxamide; or 2-(5-((3-ethoxypyrazin-2-yl)oxy)pyridin-3-yl)-N-(1-hydroxy-2-methylpropan- -2-yl)pyrimidine-5-carboxamide; or a pharmaceutically acceptable salt thereof. 9. The compound: (R)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(3-(hydroxymethyl)tet- rahydrofuran-3-yl)pyrimidine-5-carboxamide;(S)-2-(5-((3-ethoxypyridin-2-yl- )oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide; or (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(3-(hydroxymethyl)tet- rahydrofuran-3-yl)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof. 10. The compound having the structure: ##STR00035## or a pharmaceutically acceptable salt thereof. 11. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt of said compound, present in a therapeutically effective amount, in admixture with at least one pharmaceutically acceptable excipient. 12. The composition of claim 11 further comprising at least one additional pharmaceutical agent selected from the group consisting of an anti-inflammatory agent, an anti-diabetic agent, and a cholesterol/lipid modulating agent. 13. The composition of claim 12 wherein said additional pharmaceutical agent is selected from the group consisting of an acetyl-CoA carboxylase--(ACC) inhibitor, a diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitor, monoacylglycerol O-acyltransferase inhibitors, a phosphodiesterase (PDE)-10 inhibitor, an AMPK activator, a sulfonylurea, a meglitinide, an .alpha.-amylase inhibitor, an .alpha.-glucoside hydrolase inhibitor, an .alpha.-glucosidase inhibitor, a PPAR.gamma. agonist, a PPAR .alpha./.gamma. agonist, a biguanide, a glucagon-like peptide 1 (GLP-1) modulator, liraglutide, albiglutide, exenatide, albiglutide, lixisenatide, dulaglutide, semaglutide, a protein tyrosine phosphatase-1B (PTP-1B) inhibitor, SIRT-1 activator, a dipeptidyl peptidease IV (DPP-IV) inhibitor, an insulin secreatagogue, a fatty acid oxidation inhibitor, an A2 antagonist, a c-jun amino-terminal kinase (JNK) inhibitor, glucokinase activators (GKa), insulin, an insulin mimetic, a glycogen phosphorylase inhibitor, a VPAC2 receptor agonist, SGLT2 inhibitors, a glucagon receptor modulator, GPR119 modulators, FGF21 derivatives or analogs, TGR5 receptor modulators, GPBAR1 receptor modulators, GPR40 agonists, GPR120 modulators, high affinity nicotinic acid receptor (HM74A) activators, SGLT1 inhibitors, inhibitors or modulators of carnitine palmitoyl transferase enzymes, inhibitors of fructose 1,6-diphosphatase, inhibitors of aldose reductase, mineralocorticoid receptor inhibitors, inhibitors of TORC2, inhibitors of CCR2 and/or CCR5, inhibitors of PKC isoforms (e.g. PKC.alpha., PKC.beta., PKC.gamma.), inhibitors of fatty acid synthetase, inhibitors of serine palmitoyl transferase, modulators of GPR81, GPR39, GPR43, GPR41, GPR105, Kv1.3, retinol binding protein 4, glucocorticoid receptor, somatostain receptors, inhibitors or modulators of PDHK2 or PDHK4, inhibitors of MAP4K4, modulators of IL1 family including IL1beta, HMG-CoA reductase inhibitors, squalene synthetase inhibitors, fibrates, bile acid sequestrants, ACAT inhibitors, MTP inhibitors, lipooxygenase inhibitors, choesterol absorption inhibitors, PCSK9 modulators, cholesteryl ester transfer protein inhibitors and modulators of RXRalpha. 14. The composition of claim 11 further comprising at least one additional pharmaceutical agent selected from the group consisting of cysteamine or a pharmaceutically acceptable salt thereof, cystamine or a pharmaceutically acceptable salt thereof, an anti-oxidant compound, lecithin, vitamin B complex, a bile salt preparations, an antagonists of Cannabinoid-1 (CB1) receptor, an inverse agonists of Cannabinoid-1 (CB1) receptor, a peroxisome proliferator-activated receptor) activity regulators, a benzothiazepine or benzothiepine compound, an RNA antisense construct to inhibit protein tyrosine phosphatase PTPRU, a heteroatom-linked substituted piperidine and derivatives thereof, an azacyclopentane derivative capable of inhibiting stearoyl-coenzyme alpha delta-9 desaturase, acylamide compound having secretagogue or inducer activity of adiponectin, a quaternary ammonium compound, Glatiramer acetate, pentraxin proteins, a HMG-CoA reductase inhibitor, n-acetyl cysteine, isoflavone compound, a macrolide antibiotic, a galectin inhibitor, an antibody, or any combination of thereof. 15. The compound: 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyr- imidine-5-carboxamide or a pharmaceutically acceptable salt thereof. 16. The compound: 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyr- imidine-5-carboxamide. 17. The compound having the structure: ##STR00036## 18. A crystal comprising a compound having the structure: ##STR00037## or a pharmaceutically acceptable salt thereof. 19. The crystal of claim 18 having a powder x-ray diffraction pattern comprising 2-theta values of (CuK.alpha. radiation, wavelength of 1.54056 .ANG.) 5.3.+-.0.2, 7.7.+-.0.2, and 15.4.+-.0.2. 20. The crystal of claim 18 having a powder x-ray diffraction pattern comprising 2-theta values of (CuK.alpha. radiation, wavelength of 1.54056 .ANG.) 6.5.+-.0.2, 9.3.+-.0.2, and 13.6.+-.0.2. 21. A method for treating fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound. 22. A method for treating fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of two separate pharmaceutical compositions comprising (i) a first composition according to claim 12; and (ii) a second composition comprising at least one additional pharmaceutical agent selected from the group consisting of an anti-inflammatory agent, an anti-diabetic agent, and a cholesterol/lipid modulating agent and at least one pharmaceutically acceptable excipient. 23. The method of claim 22 wherein said first composition and said second composition are administered simultaneously. 24. The method of claim 22 wherein said first composition and said second composition are administered sequentially and in any order.

Details for Patent 10,071,992

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014		2039-02-26
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/18/2014		2039-02-26
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/04/2020		2039-02-26
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	07/27/2016		2039-02-26